Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Rectal organoids from subjects with cystic fibrosis can be used to assess responses to drugs that modulate CFTR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“testing of treatment responses in intestinal patient-derived organoids (PDOs) has emerged as a reliable and predictive approach118,119.”
From Human disease models in drug development (2023) · cites this paper as [118]
In the citing paper
“which are recognized as a highly valuable preclinical model to predict ex vivo therapeutic efficacy in CF patients47”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [47]
In the citing paper
“Intestinal organoids from CF patients are valuable tools to evaluate CFTR channel activity and functional recovery46–48.”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [47]
Citations
Cites
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
Self-citationSato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753 · cited 2×
“Here, rectal organoid cultures (9, 10) derived from the rectal epithelia of 71 individuals expressing 28 different CFTR genotypes (see table S1 for an overview of CFTR genotypes and mutation classification) were used to study residual CFTR function and drug-modulated CFTR function.”
MethodSelf-citationA CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195 · cited 6×
“The CFTR potentiator VX-770 (ivacaftor/KALYDECO) has been registered for treating CF caused by G551D (4, 5), S1251N, and seven other CFTR gating mutations (6), which are carried by ~5% of all people with CF.”
BackgroundInfluentialLumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver
Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., Ellis, E., van Wenum, M., Fuchs, S. A., de Ligt, J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.050 · Cited by 1,619
Self-citationGibson, L. E., & Cooke, R. E. (1959) · Pediatrics · doi:10.1542/peds.23.3.545 · Cited by 1,434 · cited 1×
“2F) (20, 21) compared to the residual CFTR function detected at other forskolin concentrations (Fig.”
BackgroundGrowing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications
Sato, T., & Clevers, H. (2013) · Science · doi:10.1126/science.1234852 · Cited by 1,170
Self-citationA functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999
Self-citationCystic fibrosis genetics: from molecular understanding to clinical application
Cutting, G. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 965
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M. P., Dunitz, J. M., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 807
Chloride impermeability in cystic fibrosis
Quinton, P. M. (1983) · Nature · doi:10.1038/301421a0 · Cited by 767 · cited 1×
“2F) (20, 21) compared to the residual CFTR function detected at other forskolin concentrations (Fig.”
BackgroundThe n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
Lillie, E. O., Patay, B., Diamant, J., Issell, B., Topol, E. J., & Schork, N. J. (2011) · Personalized Medicine · doi:10.2217/pme.11.7 · Cited by 706
Sosnay, P. R., Siklosi, K. R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., Ramalho, A. S., Amaral, M. D., Dorfman, R., Zielenski, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2745 · Cited by 630
Clancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., Ballmann, M., Boyle, M. P., Bronsveld, I., Campbell, P. W., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200393 · Cited by 515
Self-citationBoyle, M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., Huang, X., Waltz, D., Patel, N. R., & Rodman, D. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70132-8 · Cited by 452
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Yu, H., Burton, B., Huang, C.-J., Worley, J., Cao, D., Johnson, J. P., Urrutia, A., Joubran, J., Seepersaud, S., Sussky, K., et al. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.12.005 · Cited by 423 · cited 1×
“Thus far, we have been able to recapitulate most observations about responses to CFTR modulators such as VX-809 and VX-770 in primary airway cell cultures (26, 37).”
BackgroundEffect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study
McKone, E. F., Emerson, S. S., Edwards, K. L., & Aitken, M. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13368-5 · Cited by 397
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G., & Higgins, M. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.09.005 · Cited by 394 · cited 2×
“The CFTR potentiator VX-770 (ivacaftor/KALYDECO) has been registered for treating CF caused by G551D (4, 5), S1251N, and seven other CFTR gating mutations (6), which are carried by ~5% of all people with CF.”
BackgroundMechanism-based corrector combination restores ΔF508-CFTR folding and function
Okiyoneda, T., Veit, G., Dekkers, J. F., Bagdany, M., Soya, N., Xu, H., Roldan, A., Verkman, A. S., Kurth, M., Simon, A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1253 · Cited by 378 · cited 2×
“This map suggested the potential for clinical responses with VX-770 or combined VX-809 + VX-770 treatment for subjects expressing G1249R and TG(13)T(5) mutations, VX-809 + VX-770 for subjects expressing the A455E mutation, and modest potential of VX-809 + VX-770 for the individual who was compound heterozygous for R33…”
BackgroundSelf-citationIvacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation
Flume, P. A., Liou, T. G., Borowitz, D. S., Li, H., Yen, K., Ordoñez, C. L., & Geller, D. E. (2012) · Chest · doi:10.1378/chest.11-2672 · Cited by 338 · cited 1×
“3B) (6, 22, 23) and drug-induced FIS for rectal organoids quantitated in different ways [per concentration of”
Van Goor, F., Yu, H., Burton, B., & Hoffman, B. J. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.06.008 · Cited by 337 · cited 2×
“This suggested that the R347P mutation is not responsive to VX-770 treatment (26).”
BackgroundPotentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
Cholon, D. M., Quinney, N. L., Fulcher, M. L., Esther, C. R., Das, J., Dokholyan, N. V., Randell, S. H., Boucher, R. C., & Gentzsch, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008680 · Cited by 320
Middendorp, S., Schneeberger, K., Wiegerinck, C. L., Mokry, M., Akkerman, R. D. L., Wijngaarden, S., Clevers, H., & Nieuwenhuis, E. E. S. (2014) · STEM CELLS · doi:10.1002/stem.1655 · Cited by 305
Self-citationNg, B., Chu, A., & Khan, M. M. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002468 · Cited by 301
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
Veit, G., Avramescu, R. G., Perdomo, D., Phuan, P.-W., Bagdany, M., Apaja, P. M., Borot, F., Szollosi, D., Wu, Y.-S., Finkbeiner, W. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008889 · Cited by 287 · cited 2×
“The SLA assay in rectal organoids is a cumulative steady-state readout without a supraphysiological stimulus that cannot be compared directly with chronic VX-770 stimulation followed by an acute CFTR function measurement in airway cells (38, 39).”
Backgroundde Lau, W., Kujala, P., Schneeberger, K., Middendorp, S., Li, V. S. W., Barker, N., Martens, A., Hofhuis, F., DeKoter, R. P., Peters, P. J., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00434-12 · Cited by 258
Self-citationMoon, C., VanDussen, K. L., Miyoshi, H., & Stappenbeck, T. S. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.98 · Cited by 233 · cited 1×
“Recently described protocols (43) to generate 2D monolayers from 3D organoids in culture may help in the study of ion channel activities that are not coupled to fluid secretion.”
BackgroundHuman Enteroids as a Model of Upper Small Intestinal Ion Transport Physiology and Pathophysiology
Foulke-Abel, J., In, J., Yin, J., Zachos, N. C., Kovbasnjuk, O., Estes, M. K., de Jonge, H., & Donowitz, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.047 · Cited by 201
A Cystic Fibrosis Mutation Associated with Mild Lung Disease
Gan, K.-H., Veeze, H. J., van den Ouweland, A., Halley, D., Scheffer, H., van der Hout, A., Overbeek, S. E., de Jongste, J. C., Bakker, W., & Heijerman, H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507133330204 · Cited by 178
Self-citationNew pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls
Bell, S. C., De Boeck, K., & Amaral, M. D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.005 · Cited by 170
Transepithelial electrical measurements with the Ussing chamber
Li, H., Sheppard, D. N., & Hug, M. J. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.05.026 · Cited by 166
Derichs, N., Sanz, J., Von Kanel, T., Stolpe, C., Zapf, A., Tummler, B., Gallati, S., & Ballmann, M. (2010) · Thorax · doi:10.1136/thx.2009.125088 · Cited by 145
New clinical diagnostic procedures for cystic fibrosis in Europe
Boeck, K. D., Derichs, N., Fajac, I., de Jonge, H. R., Bronsveld, I., Sermet‐Gaudelus, I., Vermeulen, F. L., Sheppard, D. N., Cuppens, H., Hug, M., et al. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60009-x · Cited by 135
Self-citationNovel opportunities for CFTR-targeting drug development using organoids
Dekkers, J. F., van der Ent, C. K., & Beekman, J. M. (2013) · Rare Diseases · doi:10.4161/rdis.27112 · Cited by 101 · cited 1×
“we used a recently established forskolin-induced swelling (FIS) assay (11, 12) and developed a new assay that measures the steady-state lumen area (SLA) of organoids in the absence of forskolin.”
MethodSelf-citationde Jonge, H. R., Ballmann, M., Veeze, H. J., Bronsveld, I., Stanke, F., Tümmler, B., & Sinaasappel, M. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.05.034 · Cited by 97
Self-citationUezono, Y., Bradley, J., Min, C. K., McCarty, N. A., Quick, M. W., Riordan, J. R., Chavkin, C., Zinn, K., Lester, H. A., & Davidson, N. (1993) · PubMed · Cited by 75
Sousa, M., Servidoni, M. F., Vinagre, A. M., Ramalho, A. S., Bonadia, L. C., Felício, V., Ribeiro, M. A., Uliyakina, I., Marson, F. A., Kmit, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047708 · Cited by 67 · cited 1×
“Rectal organoids were obtained independent of age and with only limited discomfort (15, 16).”
BackgroundAssessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis
Mall, M. A., Hirtz, S., Gonska, T. Y., & Kunzelmann, K. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.05.035 · Cited by 67
Campana, S., Taccetti, G., Ravenni, N., Masi, I., Audino, S., Sisi, B., Repetto, T., Döring, G., & de Martino, M. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.03.010 · Cited by 61
Exopolysaccharides produced by Burkholderia cenocepacia recA lineages IIIA and IIIB
Chiarini, L., Cescutti, P., Drigo, L., Impallomeni, G., Herasimenka, Y., Bevivino, A., Dalmastri, C., Tabacchioni, S., Manno, G., Zanetti, F., et al. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.04.004 · Cited by 53
Applicability of interrupter resistance measurements using the MicroRint® in daily practice
Arets, H. G. M., Brackel, H., & van der Ent, C. K. (2003) · Respiratory Medicine · doi:10.1053/rmed.2002.1452 · Cited by 36
Repeatability and bronchodilator reversibility of lung function in young children
Sonnappa, S., Bastardo, C. M., Wade, A. M., Bush, A., Stocks, J., & Aurora, P. (2012) · European Respiratory Journal · doi:10.1183/09031936.00076012 · Cited by 27
Vitzthum, C., Clauss, W. G., & Fronius, M. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.09.009 · Cited by 26 · cited 1×
“Potentially, CFTR function itself may be regulated during cell stretching, although the linear swell response suggests that such an effect does not occur (41).”
BackgroundGenotype-phenotype relationship in 12 patients carrying cystic fibrosis mutation R334W.
Antiñolo, G., Borrego, S., Gili, M., Dapena, J., Alfageme, I., & Reina, F. (1997) · Journal of Medical Genetics · doi:10.1136/jmg.34.2.89 · Cited by 12
Ivacaftor in severe cystic fibrosis lung disease and a G 551 D mutation
Wood, M., Smith, D. B., Reid, D. W., Masel, P. J., France, M. W., & Bell, S. C. (2013) · Respirology Case Reports · doi:10.1002/rcr2.27 · Cited by 10 · cited 1×
“The lack of improvement of FEV1 in the other subject likely resulted from structural damage associated with severe pulmonary disease and fibrosis that may have prevented a FEV1 response to drug therapy (33).”
BackgroundA novel mutation (G1249R) in exon 20 of the CFTR gene
Dijkstra, D.-J. W., Scheffer, H., & Buys, C. H. C. M. (1994) · Human Mutation · doi:10.1002/humu.1380040213 · Cited by 6 · cited 1×
“The G1249R mutation was described previously as a mutation in exon 20 of the CFTR gene (25), but the functional impact of this mutation has not been described.”
Backgroundda Rocha, A. M., Donadio, M. V. F., de Ávila, D. V., Hommerding, P. X., & Maróstica, P. J. C. (2012) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132012000200007 · Cited by 5
Cited by
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
Self-citationHuman organoids: model systems for human biology and medicine
Kim, J., Koo, B.-K., & Knoblich, J. A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0259-3 · Cited by 2,187
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790
Self-citationProgress and potential in organoid research
Rossi, G., Manfrin, A., & Lutolf, M. P. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0051-9 · Cited by 1,182
Metadata
- Authors
- Dekkers, J. F., Berkers, G., Kruisselbrink, E., Vonk, A., de Jonge, H. R., Janssens, H. M., Bronsveld, I., van de Graaf, E. A., Nieuwenhuis, E. E. S., Houwen, R. H. J., Vleggaar, F. P., Escher, J. C., de Rijke, Y. B., Majoor, C. J., Heijerman, H. G. M., de Winter–de Groot, K. M., Clevers, H., van der Ent, C. K., & Beekman, J. M.
- Affiliations
- University Medical Center Utrecht (NL)
- Department of Gastroenterology and Hepatology, Erasmus University Medical Center, 3015 CE Rotterdam, Netherlands.
- Erasmus MC (NL)
- Department of Pulmonology, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands.
- Department of Clinical Chemistry, Erasmus University Medical Center/Sophia Children’s Hospital, 3015 CN Rotterdam, Netherlands.
- Amsterdam UMC Location University of Amsterdam (NL)
- Haga Hospital (NL)
- Department of Pediatric Pulmonology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 3584 EA Utrecht, Netherlands.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-06-22
- Volume
- 8
- Issue
- 344
- Pages
- 344ra84-344ra84
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2465114161
- Cited by
- 548
- References
- 47
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 35 · 2023: 47 · 2022: 73 · 2021: 86 · 2020: 70 · 2019: 55 · 2018: 65 · 2017: 44 · 2016: 14
- FWCI
- 52.65
- Type
- journal article
- Language
- en
- Open access
- green
- dspace.library.uu.nl
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- Dutch Cystic Fibrosis Foundation
- Wilhelmina Children's Hospital Foundation
- Dutch Health Organization ZonMw, Netherlands
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- cystic fibrosis, CFTR, patient-derived organoids, ivacaftor, lumacaftor, drug response prediction, rare CFTR mutations, F508del mutation, CFTR function, genetic background
- MeSH terms
- Aminophenols, Aminopyridines, Biological Assay, Chlorides, Cystic Fibrosis, Genotype, Humans, Mutation, Organoids, Quinolones, Cystic Fibrosis Transmembrane Conductance Regulator, Benzodioxoles, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.